Source comparison
BPC-157 Joint Support Complete Guide 2026: Comparison
BPC-157 (injected) Upregulates VEGFR2, EGFR; promotes fibroblast migration and collagen synthesis 250–500mcg SC daily for 8–12 weeks Strong animal data; limited Phase 2 human trials 6–10 weeks Most promising for tendon/ligament repair but lacks Phase 3 validat
This comparison does not assign a generated winner or score.
- BPC-157 (injected)
- Upregulates VEGFR2, EGFR; promotes fibroblast migration and collagen synthesis
- 250–500mcg SC daily for 8–12 weeks
- Strong animal data; limited Phase 2 human trials
- 6–10 weeks
- Most promising for tendon/ligament repair but lacks Phase 3 validation. Use requires comfort with off-label, research-grade compounds
- BPC-157 (oral)
- Same intended mechanism; severely limited bioavailability
- 500–1000mcg oral daily
- Low. Minimal systemic absorption
- Unclear. Likely ineffective systemically
- Not recommended for joint support due to degradation in GI tract; any effect would be localised to gut tissue
- Collagen peptides (Type I/III)
- Provides hydroxyproline and glycine as building blocks for endogenous collagen synthesis
- 10–15g daily
- Moderate. Several RCTs show modest improvements in joint pain
- 8–12 weeks
- Useful adjunct but passive; doesn't modulate repair signalling like BPC-157
- Hyaluronic acid (intra-articular)
- Lubricates joint space; may stimulate endogenous HA production
- 20–40mg injection every 6 months
- High. FDA-approved for knee OA
- 2–4 weeks
- Proven but temporary; addresses symptoms, not tissue repair
- Platelet-rich plasma (PRP)
- Delivers concentrated growth factors (PDGF, TGF-β) to injury site
- Single or series of injections
- Moderate. Inconsistent trial results
- 4–8 weeks
- Autologous source; quality depends on preparation protocol; more invasive than peptides